Edwards Lifesciences (NYSE:EW) Price Target Raised to $100.00

Edwards Lifesciences (NYSE:EW) had its target price hoisted by Mizuho from $90.00 to $100.00 in a research report released on Friday morning,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

Several other research analysts also recently commented on EW. Canaccord Genuity Group lifted their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a report on Friday, July 25th. Robert W. Baird lifted their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a report on Friday, July 25th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Daiwa America upgraded Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 29th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.00.

Edwards Lifesciences Stock Down 1.2%

EW opened at $82.48 on Friday. The company has a market cap of $48.42 billion, a P/E ratio of 11.87, a P/E/G ratio of 3.97 and a beta of 1.05. The business’s 50-day moving average price is $77.58 and its 200-day moving average price is $76.97. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 12 month low of $64.89 and a 12 month high of $87.09.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities analysts expect that Edwards Lifesciences will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.29% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

A number of hedge funds have recently modified their holdings of EW. Parkside Financial Bank & Trust increased its stake in shares of Edwards Lifesciences by 9.8% in the 2nd quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company’s stock worth $114,000 after acquiring an additional 130 shares in the last quarter. Prosperity Consulting Group LLC boosted its stake in Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares in the last quarter. NewSquare Capital LLC grew its holdings in Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after purchasing an additional 134 shares during the period. Empirical Finance LLC grew its holdings in Edwards Lifesciences by 0.6% in the second quarter. Empirical Finance LLC now owns 21,329 shares of the medical research company’s stock worth $1,668,000 after purchasing an additional 134 shares during the period. Finally, Alpine Bank Wealth Management increased its stake in shares of Edwards Lifesciences by 10.7% during the third quarter. Alpine Bank Wealth Management now owns 1,392 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 135 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.